Exploring the disconnect: mechanisms underpinning the absence of physical function improvement with SGLT2 inhibitors
Current evidence suggests sodium-glucose cotransporter 2 inhibitors (SGLT2i) do not consistently improve patient physical function, despite improvements in clinical symptoms and reductions in both adiposity and body weight. We highlight heterogenous methodologies in SGLT2i physical function trials....
Saved in:
| Main Authors: | Cian Sutcliffe, Jack A. Sargeant, Thomas Yates, Melanie J. Davies, Luke A. Baker |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Systems Biology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fsysb.2025.1593229/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a Department of Veterans Affairs quality improvement intervention
by: Shira Yun, et al.
Published: (2025-03-01) -
Liver function effects of SGLT2 inhibitor and GLP‐1 receptor agonist combination treatment in patients with type 2 diabetes (post hoc analysis of RECAP study)
by: Daisuke Tsuriya, et al.
Published: (2025-07-01) -
SGLT2 Inhibitors: From Molecular Mechanisms to Clinical Outcomes in Cardiology and Diabetology
by: Marlena Stielow, et al.
Published: (2025-07-01) -
¿Combinamos AR-GLP1 + i-SGLT2? Sí o no
by: Claudia Folino
Published: (2024-10-01) -
Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes
by: James Goodman, et al.
Published: (2025-07-01)